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Emerging antimicrobial resistance is one of the barriers in controlling pathogenic bacteria. In attempting to understand the 
emergence of antimicrobial resistance, European Member States are obliged to monitor and report antimicrobial resistance 
in zoonotic Salmonella spp., and Campylobacter spp., isolates from food-producing animals since 2003. Reporting on 
actual consumption of antimicrobial agents has been underway since 2010, together with monitoring and reporting of sales 
of veterinary antimicrobial agents since 2009, by some countries and encompassing most of the EU/EEA in later years.  
The first integrated report by the European Centre for Disease Prevention and Control (ECDC), the European Food Safety 
Authority (EFSA) and the European Medicines Agency (EMA) suggesting possible relationships between the 
consumption of antimicrobial agents and the occurrence of antimicrobial resistance was published in 2015. The scope of 
the report was limited to a comparison of consumption of antimicrobials in food-producing animals including 
Campylobacter spp., Salmonella spp., and Escherichia coli as an indicator pathogen. The antimicrobials tested for 
emerging resistance due to consumption were the fluoroquinolones, 3rd and 4th generation cephalosporins and the 
tetracyclines. Monitoring has been from, healthy animals and food for Campylobacter spp., while for Salmonella spp., 
monitoring has been on the prevalence of the bacteria. Macrolides against Campylobacter spp., only were also monitored. 
The data provides a baseline for emerging antimicrobial resistance knowledge and when and if control measures are 
working. 
Keywords: antimicrobial consumption; food borne bacteria; antimicrobial resistance 
1. Introduction 
The use (particularly the misuse) of antimicrobials in human and animal medicine has been highly associated with the 
spread of antimicrobial resistance in human and animals [1]. However, there is some evidence that exposure to 
antimicrobials has not been limited to the modern ‘antimicrobial era’. Evidence has been reported in the form of traces 
of tetracycline found in human skeletal remains from ancient Sudanese (Kush) Nubia dating back to 350–550 CE and in 
samples taken from the femoral mid-shafts of the late Roman period skeletons, from the Dakhleh Oasis in Egypt [2].  
 Multiple reports spanning the past 40 years, consistently highlighted the issue of increasing antimicrobial resistance 
since the Swann Report in 1969 [3] and the SMAC report of 1998 [4] in the UK. The rapid spread of antimicrobial 
resistance has led to various control measures especially in the agricultural use of antimicrobials. A timeline of these 
measures is outlined below. The relationship between antimicrobial consumption and growth in resistance levels for 
certain bacterial species (Campylobacter spp., Salmonella spp., and Escherichia coli) is also discussed. 
1.1   Timeline on antimicrobial control measures in Europe 
The European Union (EU) took up the mantle and a strong approach was taken and some landmark regulations have 
been enforced on the use of antimicrobial agents on European farms. Sweden banned antimicrobials in animal feed, 
following a 1984 report, which showed that consumer confidence in meat safety dropped after it emerged that 30 tons 
per year of antimicrobials were being used in Sweden in food animal production [5]. In the early 1990s, vancomycin-
resistant Enterococcus (VRE) was first found in patients in Europe [6], resulting in an EU wide ban on the use of 
avoparcin in agriculture in 1997 (Directive 97/6/EC amending Directive 70/524 [7]. In 1999, the Steering Committee of 
the European Commission (EC) recommended phasing out the use of medically important antimicrobials as growth 
promoters and implementing disease prevention methods [8]. Since 2006, all veterinary use of antimicrobials requires a 
prescription (POM status, prescription-only medicines), and that all licensed veterinary antimicrobial products are 
prescription only drugs [9].  
 A communication from the EC in 2011, outlined a plan to address the growing issue of antimicrobial resistance and 
finalised in 2014 [10]. Some countries have been more active including developing their own country-specific reports 
from committees that look at both antimicrobial use information and susceptibility levels e.g. Denmark [11], the 
Netherlands [12], Germany [13], Sweden [14], and Norway [15]. The British Prime Minister commissioned a ‘Review 
on Antimicrobial Resistance’, under the auspices of the Wellcome Trust and the British Government [16], to raise 
awareness of antimicrobial misuse. The EU began to host an Antimicrobial Awareness Day on 18th November every 
year (starting in 1998), across Europe. 
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1.2   Timeline on antimicrobial control measures in the US 
In the United States, new animal antimicrobial labelling was adopted when the Food and Drug Association (FDA) 
prohibited the extra-label use of fluoroquinolones and glycopeptides in food-producing animals in 1997 [17] another 
class of antimicrobials (cephalosporins) was added to this list in April of 2012 [18]. 
 In 2003 an entirely new approach was undertaken to address the microbial safety of new antimicrobial drugs in the 
form of Guidance for Industry (GFI) 152 [19]. This procedure outlined a risk assessment based approach for evaluating 
the microbial food safety of antimicrobial animal drugs. In 2003, the National Antimicrobial Resistance Monitoring 
System – Enteric Bacteria (NARMS) was set up, coordinated by the Centre for Disease Control (CDC) in partnership 
with the FDA and US Department of Agriculture (USDA), together with health departments at both state and local level 
[20]. This new monitoring system exposed some general trends in antimicrobial resistance, including a rise in resistance 
levels for beta-lactam antimicrobials amongst Enterobacteriaceae. Conversely, resistance to several other classes of 
antimicrobial, including critically important classes such as fluoroquinolones exhibited very low levels of resistance in 
salmonella, suggesting that the new policy measures were having an effect. Doyle et al [21] and Barclay [22] provide a 
comprehensive summary of the US activities on antimicrobial use and monitoring policies. The CDC-US issued a 
substantial report on antimicrobial resistance threats in 2013 [23]. 
1.3   Global approaches to tackling emerging antimicrobial resistance 
A host of intergovernmental agencies worldwide have taken an interest in the emerging antimicrobial resistance threat, 
such as the World Health Organisation (WHO), whose activities in this area started in 1971, with a collaborative study 
on antimicrobial sensitivity testing methodologies [24]. National bodies have their own antimicrobial susceptibility 
testing systems in operation [25], with harmonised methods only now beginning to develop across Europe e.g. with 
EUCAST [26].  
 In 1981, the WHO established a scientific working group on antimicrobial resistance [27]. Workshops on global 
strategy approaches occurred in 2001 and 2002 [28, 29] with options for action, incorporating five domains, based on 
the 2001 global strategy recommendations [30]. This eventually led to the six-point policy package that was presented 
on World Health Day, April 2011 [31], under the theme "Combat Drug Resistance". WHO called for urgent and 
concerted action by governments, health professionals, industry, civil society and patients to slow down the spread of 
drug resistance, to limit the impact of drug resistance today and preserve medical advances for future generations [31]. 
The WHO six point policy package included: Monitoring of antimicrobial resistance and use; the rational use and 
regulation of antimicrobials; Antimicrobial use in animal husbandry; Infection prevention and control; the nurturing of 
innovation and political commitment [32]. 
 The World Health Assembly (WHA) Resolution of 1998 [33], pressed Member States to develop procedures to 
encourage the suitable and cost effective use of antimicrobials. At the 67th World Health Assembly, in May 2014, 
Member States approved a resolution, WHA67.25, requesting the WHO to draft a global plan of action on antimicrobial 
resistance. At the 68th World Health Assembly in March 2015, this global plan was formulised [34]. 
 
The building blocks that are considered prerequisites to combat antimicrobial resistance include:  
• Comprehensive plans at national level,  
• Laboratory capacity to undertake surveillance for resistant microorganisms,  
• Access to safe, effective antimicrobial medicines,  
• Control of the misuse of these medicines,  
• Awareness and understanding among the general public and effective infection prevention and control 
programmes [35]. 
  
 The Codex Alimentarius Commission (CAC) is recognized by the World Trade Organization, as an international 
reference body for the resolution of disputes that concern both food safety and consumer protection. As of 2012, there 
were 186 members of the CAC: 185 member countries and one member organization, the European Union (EU). The 
CAC has published many reports on use of veterinary drugs [36, 37] and on minimizing and containing antimicrobial 
resistance [38]. A task force on antimicrobial resistance was set up in 2007 which formulated strategies for undertaking 
risk analysis for food borne antimicrobial resistance [39]. 
 The OIE (Office International des Epizooties), now known, as the World Organization for Animal Health, was 
established in 1920, due to an infection of rinderpest which occurred suddenly in Belgium as a consequence of infected 
zebra that originated in India and intended for Brazil, transiting via the port of Antwerp [40]. The OIE reports on 
infection worldwide, so that countries can take precautionary preventative measures. Information is also provided by 
OIE on diseases transmissible to humans and international introduction of pathogens. The OIE also has a role in 
highlighting antimicrobial resistance and set up committees in 2003 to consolidate and update its publication on 
Terrestrial Animal Health Codes [41] and proposed a list of critically important antimicrobials for veterinary use in 
2007 [42]. The OIE organised the first Global Conference “On the Responsible and Prudent use of Antimicrobial 
Agents for Animals”, in Paris in March 2013, where all the national, regional and global experts and stakeholders in the 
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field of pharmacology, epidemiology, animal and human, discussed the situation on antimicrobial use worldwide and 
antimicrobial resistance, all the presentations are available on the OIE website [43]. Suggested alternatives to 
antimicrobials at the conference included; metals; host antimicrobial peptides (recombinant); essential oils; 
bacteriophage; immunomodulants etc. An OIE report published in 2014, outlined standards, recommendations and work 
to date of the OIE on antimicrobial resistance [44]. The OIE recommends permanent risk assessment is carried out in 
parallel with the use of antimicrobials which will ensure the health and welfare of animals [45].  
 The World Economic Forum has identified antimicrobial resistance as a global risk [46]. The growing global threat 
of antimicrobial resistance was recognised by US President Obama, the Swedish Prime Minister and then-European 
Council President Reinfeldt and European Commission President Barroso at the 2009 US–EU summit. The summit 
declaration called for the establishment of - “a transatlantic taskforce on urgent antimicrobial resistance issues focused 
on appropriate therapeutic use of antimicrobial drugs in the medical and veterinary communities, prevention of both 
healthcare- and community-associated drug-resistant infections, and strategies for improving the pipeline of new 
antimicrobial drugs, which could be better addressed by intensified cooperation between us”. The Transatlantic 
Taskforce on Antimicrobial Resistance (TATFAR) was constituted, based on this declaration [47].  
 However, multiple factors can influence antimicrobial decision-making in different jurisdictions around the world; 
there are many different ethical, social and cultural bases for the use of these products in farming [48]. It is commonly 
accepted that greater levels of antimicrobial usage leads to greater selective pressure that favours resistance, and 
consequently, lower usage levels favour susceptible bacteria [49]. Antimicrobial resistance is a complex global issue 
which cannot be solved by any one country acting in isolation. A target for the G20 summit in Hangzhou, China in 
November 2011 is to reunite the world in the fight against antimicrobial resistance [50]. 
1.4   Monitoring of the spread of antimicrobial resistance 
Monitoring programmes on the incidence and progress of antimicrobial resistance and consumption of antimicrobial 
agents are extremely desirable. The EU set out 12 key actions (Road Map) for a successful fight against antimicrobial 
resistance in its action plan against the rising threats from antimicrobial resistance. Actions 9 and 10 are requests to 
“Strengthen surveillance systems on AMR [antimicrobial resistance] and antimicrobial consumption in human medicine 
(action no 9) and in animal medicine (action no 10)” [51]. 
 European and international professional bodies have developed several strategies, recommendations and treatment 
guidelines on responsible use of antimicrobials, these include EPRUMA (European Platform for the Responsible Use of 
Medicines in Animals) [52], FVE (Federation of Veterinarians of Europe) [53] and HMA (Heads of Medicine 
Agencies) [54]. National antimicrobial resistance programmes have also been established in the EU Member States. 
 The bacterial species monitored and the antimicrobial agents tested, as well as the methodology used differ between 
agencies making comparison difficult. For instance, some agencies report clinical breakpoints, whereas others report 
antimicrobial susceptibility by means of epidemiological cut-off values for most of the antimicrobials tested. 
Additionally some of the agencies may have included reports on consumption of antimicrobials, but as for resistance the 
level of detail differs. Hence for example, in the Danish reports, data can be obtained down to the individual herd level 
and are reported by drug class and animal species each year. In the majority of other countries e.g. Ireland, only total 
consumption for all animal species can be obtained.  
 However, the data still provides useful information regarding trends that may occur over time and the potential 
differences between countries. Data that contains further information on animal population, along with antimicrobial 
agents and a relationship between resistance and consumption of the antimicrobials can be established [55]. The 
European Medicines Agency (EMA) estimates the amount of antimicrobial products consumed in treatment and growth 
promotion in food animals. These reports allow for studies to examine the feasibility of associations between the 
presence of resistant organisms and the consumption of antimicrobials. EU countries are obliged, but to date it is based 
on voluntary reporting, to submit data on antimicrobial resistance in humans based on the EU Directive No 1082 [56].  
2. Monitoring Consumption of Antimicrobials in the EU 
Monitoring the use of antimicrobials and the level of antimicrobial resistance has been underway in Europe since 2003, 
and of consumption of antimicrobials since 2010, by the European Surveillance of Antimicrobial Consumption Network 
(ESAC-Net) and published by the European Centre for Disease Control (ECDC). The reports are based on antimicrobial 
consumption data from the community (primary care sector) and the hospital sector. The report for 2010 was from data 
from 24 EU Member States and two European Economic Area (EEA) non-EU countries, Iceland and Norway [57]. Two 
further reports for 2011 [58] and for 2012 [59], from the 28 EU Member States and again the two EEA countries are 
available. 
 Much of the concern about inappropriate antimicrobial prescribing and the possible emergence of antimicrobial 
resistance in animals is focused on the potential transfer of resistance via the food chain. Antimicrobials may only be 
supplied for use in animals under veterinary prescription in accordance with European Commission directive 
2001/82/EC [60]. The major aims of these strategies and legislative regulations are to encourage veterinarians to 
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prescribe prudently and responsibly and furthermore to reduce antimicrobial use. Decisions made by veterinarians in 
treating animals reflect an ethical requirement to improve and maintain animal health. There are multiple situations for 
limiting antimicrobial usage under a variety of voluntary, regulatory and legal policy frameworks going back to the first 
feed additive directive 70/524 in 1970 [61] that was amended in 1997 [62]. 
2.1   Consumption of antimicrobials in humans and food-producing animals in the EU in 2012 
An in-depth analysis and summary by the ECDC, the European Food Safety Authority (EFSA) and the EMA was 
compiled for 2012 and published in January 2015 [63]. This, the first joint report on the integrated analysis of the 
consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-
producing animals, suggested that there is a possibility of a connection between the consumption of antimicrobial 
agents and the incidence of antimicrobial resistance in humans and food-producing animals. The countries providing 
information included, the 28 Member States (MS). The EU Member States include: Austria; Belgium; Bulgaria; 
Croatia; Cyprus; Czech Republic; Denmark; Estonia; Finland; France; Germany; Greece; Hungary; Ireland; Italy; 
Latvia; Lithuania; Luxembourg; Malta; Netherlands; Poland; Portugal; Romania; Slovakia; Slovenia; Spain; Sweden; 
United Kingdom. In addition data from Iceland, Norway and in some cases Switzerland was obtained. The scope of this 
study was restricted to a comparison of antimicrobial consumption in both food-producing animals and humans and to 
the analysis of the occurrence of antimicrobial resistance to certain types of antimicrobial in selected bacterial species. 
Examples are outlined in Table 1. An in-depth analysis was also carried out on the association between consumption of 
carbapenems in human medicine and carbapenems resistance in bacteria isolated from humans. 
 
Table 1   Antimicrobials consumed and bacteria tested for antimicrobial resistance in the EU analysis. 
Species tested Antimicrobial tested 
Campylobacter spp. Fluoroquinolones 
Salmonella spp. 3rd - and 4th-generation cephalosporins 
Escherichia coli (indicator /pathogen) Tetracycline 
 Macrolides (Campylobacter spp., only) 
 
 The information for the report was obtained from laboratories which submitted data to the following networks: 
ECDC; European Antimicrobial Resistance Surveillance Network (EARS-Net); The European Surveillance 
Antimicrobial Consumption Network (ESAC-Net) and the Food and Waterborne Diseases and Zoonosis Network 
(FWD-Net).   
 The ECDC submitted the final report for approval to agencies who supplied the data and to the EFSA’s Scientific 
Network for Zoonosis Monitoring Data and its BIOHAZ Panel. To the European Surveillance of Veterinary 
Antimicrobial Consumption network (ESVAC) and to the Committee for Medicinal Products for Veterinary Use 
(CVMP). An outline of the results presented in this report follows. 
2.2   Comparison of biomass corrected consumption of antimicrobials in humans and food-producing animals 
in the EU in 2012 
In 2012, 3400 tonnes of antimicrobials were sold for human use and 7982 tonnes of antimicrobials were sold for food 
producing animals in the 26 EU/EEC, where data was available. The use of antimicrobials in humans is reported by 
ESAC–Net by use of the indicator DDD (defined daily dose) per 1000 inhabitants and per day. Veterinary monitoring is 
reported by ESVAC as milligrams per PCU (population correction unit) (mg/PCU). Data from ESAC-Net was 
converted into milligrams per kilogram estimated antimicrobials consumed (Figure 1).  Results to note include: 
Estimated biomass was on average 116.4 mg/kg in humans (range 56.7 in the Netherlands – 175.8 France mg/kg); 
estimated biomass was 144 mg/kg in animals (range 3.8 in Norway - 396.5 mg/kg in Cyprus); consumption was lower 
in animals (<56 mg/kg), than humans in 12 of the 26 countries. (The Netherlands was lowest at 56.7 mg/kg); in eight 
countries there was a higher consumption in animals than in humans. 
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Fig. 1   Comparison of biomass corrected consumption of antimicrobials in Humans (blue) and Food-Producing Animals (red) by 
Country in 26 EU\EEA in 2012. Data sourced from ref 63. 
 
 The crude comparison of consumption of selected antimicrobials in humans and animals has limitations in its 
determination and must be interpreted with caution. It was shown that antimicrobials of the penicillin, macrolide and 
fluoroquinolones class were the main selling antimicrobial classes in human medicine, with tetracycline, penicillin and 
sulphonamide classes the highest selling for food-producing animals. In determining a method for presentation of the 
data obtained from the EU countries, the data was analysed using logistic regression, to predict if select organisms 
developed resistance correlated to consumption of antimicrobials by country. 
 The 3rd and 4th -generation cephalosporins are regarded by WHO [64] as Critically Important Antimicrobials (CIA) 
and were analysed for the report.  Over 70% of the consumption of the 3rd  and 4th -generation cephalosporins was 
reported for hospital/human use (range 30-98%). The average consumption (population-weighted mean) for humans 
was 3.50 mg/kg (range 0.02–12.52 mg/kg) and for food-producing animals 0.24 mg/kg (range < 0.01–0.68 mg/kg) 
estimated biomass. No significant correlation could be found within countries between the use of 3rd - and 4th-
generation cephalosporins for humans and for food-producing animals (Spearman’s rank correlation, rho = 0.32). 
 Fluoroquinolones are also CIAs of highest priority and are mostly used in the community. The population-weighted 
mean consumption of fluoroquinolones (mg) per estimated biomass (kg) in humans was 7.04 mg/kg and in food-
producing animals was 2.47 mg/kg estimated biomass. The corresponding ranges were 2.24–16.03 (human) and 0.01–
10.98 mg/kg (food-producing animals). A weak correlation was found within countries between consumption of 
fluoroquinolones in humans and food-producing animals (Spearman’s rank correlation, rho = 0.63). 
2.3   Comparison of consumption of selected antimicrobial classes in food-producing animals and resistance 
of bacteria in food-producing animals in 26 EU\EEA in 2012 
Analysis was carried out on consumption of tetracycline, 3rd and 4th -generation cephalosporins, macrolides and for 
fluoroquinolones and other quinolones and emerging resistance in E. coli and Salmonella spp., from cattle, domestic 
fowl and pigs and for C. coli and C. jejuni from cattle and domestic fowl.  
 The logistic regression analysis of the data to predict association between consumption and resistance, showed a 
positive association between the national consumption of tetracycline and emerging resistance observed by the bacteria 
monitored. With regard to the 3rd -4th generation cephalosporins, reduced susceptibility to cefotaxime was analysed, and 
a significant association observed. For macrolides consumption, resistance to erythromycin was analysed and again a 
positive association was observed. Campylobacter spp., tested (C. coli and C. jejuni) showed a significant positive 
association. The national consumption of fluoroquinolones and other quinolones and the risk of reduced susceptibility 
to ciprofloxacin were assessed and positive associations for both fluoroquinolones and other quinolones recorded in E. 
coli, Salmonella spp., and C. jejuni. 
 These results did not consider areas such as: dosing age regime; time of treatment in the animal life and interval 
between slaughter. In addition old drugs e.g. tetracyclines have been used therapeutically (50 years) and as growth 
promoters (25 years), so history or exposure and co-selection of resistance genes need to be considered.   
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2.4   Comparison of consumption of selected antimicrobial classes in humans and resistance of bacteria in 
humans in 26 EU\EEA in 2012 
The 3rd and 4th-generation cephalosporin consumption in hospitals and in the community analysed showed significant 
association between resistance and consumption for all counties. A positive correlation between the 3rd and 4th-
generation cephalosporins use from eight countries in hospitals and occurrence of resistance in Salmonella spp., was 
found. 
 The quinolone consumption by humans was almost exclusively fluoroquinolones with there being a strong 
correlation between resistance to this class of antimicrobials and consumption in the community being observed from 
blood steam infections (BSI) isolated E. coli (Table 2). With regards to emerging resistance in Salmonella spp., (S. 
Enteritis and S. Typhimurium) no correlation on consumption 3rd and 4th-generation cephalosporin in humans and 
resistance in humans could be found.  
 For fluoroquinolones resistance in C. coli, a positive correlation was found between consumption of fluoroquinolones 
and consumption in the community. This is thought to occur due to potential cross contamination from poultry or 
possibly from imported companion animal, food treats e.g. pig ear treats [65]. Macrolide consumption in humans and 
the incidence of erythromycin resistance was analysed from the community, hospitals and in total. For C. coli (in 14 
countries) a positive correlation was observed. For C. jejuni (16 countries), no correlation was observed. However, as 
only a small number of countries provided data, therefore the outcomes should be interpreted with caution.   
 No significance for tetracycline use in humans and resistance in S. Typhimurium (p=0.96) (Table 2), or other 
Salmonella spp., in humans or for Campylobacter spp., (C. coli and C. jejuni) was observed. The high level of 
resistance to tetracycline could be due to co-selection and the spread of clones from food-producing animals. An 
unusual occurrence of a tetracycline reservoir from imported mice for pet (e.g. reptiles) food has been put forward as an 
example [66]. 
 Carbapenems possess a very broad spectrum of activity and are active against both Gram-positive and Gram-negative 
bacteria and are considered as antimicrobials of last resort in recent emergence of multidrug-resistant cases. Resistance 
to carbapenems is increasing throughout the world [67]. Overall 16282 Klebsella pneumonia isolates from BSI’s were 
reported of which 1235 were resistant to carbapenems. Greece, with the highest consumption of carbapenems, showed 
the highest resistance to K. pneumonia (60.5%), with Italy (28.8%) and Romania (13.7%) following. The logistic 
regression analysis of the data showed a positive correlation between consumption in humans and resistance in human 
isolates. Some argue that resistance was obtained from travel to high incident countries outside the EU. Other concerns 
include the reported presence of carbapenemases producing Acinetobacter spp., in both cattle from France and horses 
from Belgium [68, 69]. Carbapenems resistance has also been reported in Salmonella spp.,and E. coli from livestock 
and pigs [70, 71]. This has resulted in extending the monitoring and reporting to extended spectrum beta-lactamases 
(ESBL’S), AmpC beta–lactamases (AmpC) and carbapenemases in Salmonella spp., and E. coli by the EU for Member 
States [72]. 
 
Table 2   Antimicrobial consumption in humans and probability of antimicrobial resistance in bacteria from humans. 
Organism  Antimicrobial consumed p- value                              
E. coli* 3rd-4th  Generation Cephalosporins <0.005 
E. coli Fluoroquinolones <0.001 
Salmonella Typhimurium  Tetracycline  0.96                            
Klebsella pneumonia  Carbapenems 0.002 
*tested for 3rd generation cephalosporins resistance  
2.5   Comparison of consumption of selected antimicrobial classes in food-producing animals and resistance 
of bacteria in humans in 26 EU\EEA in 2012 
The most prevalent food borne pathogen in the EU Member States in 2013 was Campylobacter spp., caused by broiler 
meat with C. jejuni being the most prevalent in humans. In 2013, a total of 5196 food-borne outbreaks, including 
waterborne outbreaks, were reported in the EU [73]. Most of these food-borne outbreaks were caused by Salmonella 
spp., followed by viruses, bacterial toxins and Campylobacter spp., in 28.9% of all outbreaks the causative agent was 
unknown [73]. The common Salmonella serovar was Enterititis which is often resistant to fluoroquinolones and 
Typhimurium which is multi-resistant. Campylobacter species were, C. jejuni which is the most dominant and C. coli. 
The analysis therefore was based on these organisms (Table 3). 
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Table 3   Antimicrobial consumption in food producing animals and antimicrobial resistance in bacteria from humans. 
Organism  from Humans Antimicrobial consumed  
in animals  
      p 
E. coli 3rd-4th  Generation Cephalosporins   NS* 
E. coli Fluoroquinolones <0.05 
E. coli Other quinolones  <0.001 
S. Typhimurium Tetracycline <0.05 
Salmonella spp. Tetracycline <0.001 
Campylobacter jejuni Tetracycline <0.001 
Campylobacter jejuni Macrolides <0.05 
NS: Not Significant 
 For 3rd-4th generation cephalosporins consumption in food-producing animals and probability of cephalosporin 
resistance in E. coli from BSI’s in humans, no significance (NS) was found. A slight positive correlation for Salmonella 
spp., was observed, however, it was not statistically significant. Similarly for fluoroquinolones resistance in Salmonella 
spp., and Campylobacter spp., no significant was found for consumption in food-producing animals and resistance in 
human isolates. However, for E. coli from BSI’s, a positive association was observed for fluoroquinolones and other 
quinolones. Again travel or transmission between humans could be a factor. 
     For tetracycline a positive association was seen for Salmonella spp., and Campylobacter spp., (Table 3). Possible 
relationships between occurrence of resistance to erythromycin in C. jejuni isolates from humans and total consumption 
of macrolides in animals in 2011-2012, demonstrated a significant positive association. 
3. Conclusions 
In summary, although the data analysed in the first integrated analysis of the consumption of antimicrobial agents and 
occurrence of antimicrobial resistance in bacteria from humans and food-producing animals [63], should be used with 
caution, due to reporting vigilance in some countries as against others to date. Factors such as co-selection of 
antimicrobial resistance genes and cross resistance; movement of people and animals; importation of contaminated food 
from outside the EU; cross contaminating from pets and pet food and the increasing prevalence of exotic pets in homes 
across Europe, could have misrepresented the results. More than 200 million pets are estimated to be in the EU [74]. 
Overall, the association between consumption of selected antimicrobials and the occurrence of resistance in the selected 
bacteria monitored were mostly observed. The on-going collaboration by the ECDC, EFSA and EMA on developing 
harmonising approaches to the collection of data and antimicrobial susceptibility methodologies, more detailed 
enhanced data on consumption of antimicrobials in specific animal species and hospital usage will allow for 
standardised data and conclusions to be more authentic.  The EUCAST programme for harmonising and standardisation 
of antimicrobial testing methods and interpretation of breakpoints will allow for comparative European wide results to 
be analysed. 
 
The ECDC/EFSA/EMA (2015) [63] report can be summarised as follows:  
Consumption of antimicrobials in humans and resistance in bacteria from humans 
 A positive association between 3rd –4th  generation cephalosporins consumption in humans and  cephalosporin 
resistance in E. coli from  humans was observed. 
 A strong association between consumption of fluoroquinolones in humans and resistance in E. coli was 
observed. No correlating was found for Salmonella spp. Some correlating was found for community 
consumption of fluoroquinolones and resistance to C. coli in humans. For Salmonella spp., and Campylobacter 
spp., low numbers of human isolated were tested.  
Consumption of antimicrobials in food-producing animals and resistance in bacteria from food-producing animals 
 Overall, a strong association was found for consumption of antimicrobials tested and resistance in the organism 
tested. In particular for E. coli and less so for Salmonella spp., and Campylobacter spp. 
Consumption of antimicrobials in food-producing animals and resistance in bacteria from humans 
 The incidence of resistance in E. coli that have caused blood stream infections could be correlated with 
consumption of antimicrobials in food-producing animals and also in humans. 
 A positive association between consumption of cephalosporins in humans (use in hospitals and in total) and 
resistance was observed in the organisms tested. 
 For fluoroquinolones a positive correlation was observed with consumption in the community but not with 
consumption in hospitals. 
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 Can the outbursts of concerns since the Swan report in 1969 [3] to the present day national and numerous 
intergovernmental and professional body reports on antimicrobial resistance emergence, make any difference or will 
they sit on the shelf? Alternative to antimicrobials including novel agents e.g. metals, antimicrobial peptides 
(recombinant), essential oils, bacteriophage, immunomodulants and the recent isolation of a novel antimicrobial 
teixobactin, which was isolated from uncultivable organisms in soil and shows a new path for antimicrobial discovery 
[75]. A political as well as corporate will is required together with target involvement of medical and veterinary 
professionals and with societal attitudes taking the challenge on board. But as global crisis’s emerge including; income 
disparity and financial failure, natural catastrophes from climate and water shortages, population ageing and war and 
refugee migration, the emerging antimicrobial problem moves down the global risk priority. 
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